Cataract Progression After Intravitreal Triamcinolone Injection - 18/08/11
Résumé |
Purpose |
To assess cataract progression after intravitreal triamcinolone injection.
Design |
Retrospective, interventional, case-control study.
Methods |
Forty-two phakic eyes of 37 patients were injected one, two, or three times with intravitreal triamcinolone for various indications. Noninjected phakic fellow eyes served as the control. The mean follow-up time for single injection was 12 months, for multiple injections was 14 months, and for control group was 13 months. Lens status, best-corrected visual acuity, and refractive errors were recorded at baseline and at each follow-up examination.
Results |
At the last follow-up, changes in posterior subcapsular cataract and refractive error from baseline were significantly different between single triamcinolone-injected eyes and the control group [0.7 ± 0.2 (mean ± SEM [arbitrary unit] vs 0.2 ± 0.1, P = .02; and −0.5 ± 0.1 diopter vs −0.2 ± 0.1 diopter, P = .01, respectively). For multiple-injected eyes and control eyes, change from baseline in corticonuclear cataract (1.1 ± 0.2 vs 0.2 ± 0.1), posterior subcapsular cataract (1.1 ± 0.2) and refractive error (−1.8 ± 0.4 diopters) were significantly different (P < .001, P < .001, and P < .001, respectively). Visual acuity did not change after single injection (P = .83) and in control group (P = .19) but decreased after multiple injections (P = .006). Eleven study eyes and two control group eyes underwent cataract extraction during study period. Corticonuclear and posterior subcapsular cataract progression significantly correlated with follow-up time (P = .003 and P = .02, respectively) and number of injections (P = .01 and P = .04, respectively).
Conclusions |
Single intravitreal triamcinolone injection induces posterior subcapsular cataract development, whereas multiple injections result in all-layer cataract progression.
Le texte complet de cet article est disponible en PDF.Plan
Vol 139 - N° 6
P. 993-998 - juin 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?